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Fumito Kuranishi1* and Tadao Ohno2,3Abstract
Skeletal metastasis of breast carcinoma is refractory to intensive chemo-radiation therapy and therefore is assumed
impossible to cure. Here, we report an advanced case of breast cancer with vertebra-Th7 metastasis that showed
complete response to combined treatments with formalin-fixed autologous tumor vaccine (AFTV), palliative
radiation therapy with 36 Gy, and adjuvant chemotherapy with standardized CEF (cyclophosphamide, epirubicin,
and 5FU), zoledronic acid, and aromatase inhibitors following mastectomy for the breast tumor. The patient has
been disease-free for more than 4 years after the mammary surgery and remains well with no evidence of
metastasis or local recurrence. Thus, a combination of AFTV, palliative radiation therapy, and adjuvant
chemotherapy may be an effective treatment for this devastating disease.
Keywords: Tumor vaccine, Mammary carcinoma, Bone metastasis, EradicationBackground
Severe pain from secondary conditions encumbers the
mobility of cancer patients and therefore compromises
their quality of life. Skeletal metastasis is one such con-
dition, which generally complicates the treatment of can-
cers. Metastasized breast carcinomas are frequently
found in the rib, vertebrae, or pelvis, and are generally
refractory to radiation therapy combined with standard-
ized chemotherapy comprising cyclophosphamide,
epirubicin, and 5FU (CEF) [1]. Zoledronic acid and aro-
matase inhibitors are not expected to cure the breast
carcinomas with bone metastasis, although they are ef-
fective in restraining further progression of the cancer
and can significantly improve overall survival [2] and
disease-free survival [3], respectively. However, we have
observed during a period of 10 years until the end of
2006 more than 300 cases of mammary carcinoma with
bone metastasis, and all patients showed downhill course
resulting in fatality despite administration of intensive* Correspondence: ishikai@beach.ocn.ne.jp
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distribution, and reproduction in any mediumchemo-radiation therapy. Here, we report a case of
breast carcinoma with apparent bone metastasis that
showed a complete response to combined treatments
with formalin-fixed autologous tumor vaccine (AFTV),
palliative radiation therapy, and adjuvant chemotherapy.Case presentation
A 52-year old woman presented with a right breast lump
(4.2 × 3.0 × 4.5 cm), which was diagnosed as breast carcin-
oma by mammography, ultrasonography, ultrasonography-
guided aspiration biopsy cytology (ABC), computed tomog-
raphy (CT), and magnetic resonance imaging (MRI). Fur-
ther, by bone scintigraphy with 99mTc, we also found a
strong uptake at the location of vertebra Th7 (Figure 1a,d),
which was the cause of back pain and corresponded to a
metastasized tumor, 3.0 cm in diameter, as assessed by MRI
and CT (Figure 1b,c). We performed right modified radical
mastectomy on 7 August 2006, and pathologically identified
the tumor as mucinous carcinoma. None of the 16 tumor-
draining lymph nodes tested so far revealed any carcinoma
cells.
Since the patient strongly desired to be treated with a
new tumor vaccine, we prepared AFTV with 3.0 g ofCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Images before and after autologous formalin-fixed tumor vaccine (AFTV) treatment, palliative radiotherapy, and adjuvant
chemotherapy. a) 99mTc-whole body scan, b) magnetic resonance image (MRI), and c) single photon emission computed tomography (SPECT-
CT) image before surgical resection of the primary tumor on 31 June 2006. d) Expanded image of ‘a’ at the site of vertebra Th7 on 31 June 2006,
e) 1 year later, and f) 4 years later at the same site.
Table 1 Details of the adjuvant chemotherapy
administered to the patient following the concomitant





Zoledronic acid, 4 mg, once a month
2006.10.31 to 2007.4.10 CEF (cyclophosphamide 100 mg/day ×
14 days + once a week with 50 mg
epirubicin and 500 mg 5FU, 2 weeks), 6
courses
2007.05.01 to 2008.03.15 Anastrozole, 1 mg/day
2008.03.11 to 2011.11.30 Exemestane, 25 mg/day
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tissues as previously described [4]. The vaccination
started on 27 August 2006, and continued once a week
for 3 weeks. Concomitantly, palliative radiation therapy
was carried out from 28 August to 12 September. A total
dose of 36 Gy of X-ray (3 Gy per day, 12 fractions) was
given to the local site of bone metastasis. The treatment
course was uneventful; there were no adverse effects.
Delayed-type hypersensitivity (DTH) response [4],
tested with the patient’s fixed tumor fragments but with-
out any immunoadjuvant, was negative (no erythema
was observed) before the first AFTV injection. However,
after leaving our hospital on 15 September 2006, the
DTH response became pseudo-positive with presence of
a 5 × 5 mm erythema. The DTH test was re-performed
on 14 February 2012 (5.4 years later) and was once again
pseudo-positive with presence of a 7 × 7 mm erythema.
Starting from 24 October 2006, the patient was also
given adjuvant chemotherapy comprising six courses of
CEF, zoledronic acid, and aromatase inhibitors (Table 1).
The high activity in vertebra Th7 shown by scintigraphy
diminished a year later (Figure 1e), becoming fainter and
fainter by December 2009, and stabilized to a scar-like
background signal level 4 years later (Figure 1f ). At
present, more than 6 years after the primary surgery, thepatient remains well with no evidence of metastasis or
local recurrence.
Conclusions
Before encountering the present case, none of our pa-
tients had ever undergone complete eradication of
breast carcinoma with bone metastasis after radiation
therapy and adjuvant chemotherapy. It is well known
that irradiation of bone metastases is a palliative treat-
ment, which was concluded from results based on 16
randomized trials, 20 prospective studies, 5 retrospective
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patients [5]. Therefore, it is extremely rare to observe
complete eradication of skeletal metastases. Particularly
in the trunk area, conventional full dose irradiation (50
to 60 Gy), which may cause late radiation injury of
major organs, should be avoided, and lower doses, such
as 36 Gy used for pain suppression during palliative
therapy, are unable to eradicate the skeletal metastases.
Moreover, no adjuvant chemotherapeutic regimen has
been found to effectively treat skeletal metastasis of
breast carcinomas.
We have observed that X-ray irradiation upregulated
glioma cell immunogenicity [6]. This phenomenon sug-
gests that the combination of irradiation and immuno-
therapy is a good candidate as a therapeutic approach
against malignant cells [7-9], and moreover, it has been
shown that this combination treatment can enhance
anti-tumor effects [10-12]. Thus, the treatment course of
the present patient with the additional immunotherapy,
AFTV, is considered to be well justified.
There is currently no clinically established system
available for estimation of anti-tumor cellular immune
reactivity. Since DTH testing is commonly used to meas-
ure specific anti-tumor cellular immune reactivity, we
used it to evaluate the anti-tumor cellular immune status
just before and later after AFTV treatment. The reactiv-
ity was revealed to be pseudo-positive 2 weeks after the
last AFTV injection in the present case, which lasted for
more than 5 years. Therefore, we assumed that a cellular
immune response against the carcinoma was induced by
the AFTV treatment, though weakly and very slowly,
and cooperated with X-ray irradiation and chemotherapy
to contribute to the eradication of skeletal metastasis of
the breast carcinoma.
Breast cancer is generally not considered as just one
disease, but a heterogeneous collection of distinct en-
tities that are molecularly quite different [13]. We there-
fore assume that whole autologous tumor tissue should
contain the full set of tumor-associated antigenic pep-
tides derived from the heterogeneous collection within
the primary tumor. In the present case, we used a mix-
ture of both paraffin-embedded and formalin-fixed au-
tologous tumor tissues as the source of tumor antigens.
We aimed to incorporate the original tumor antigens
in the breast carcinoma as well as any possible alter-
ations of the expressed tumor antigens in the progressive
tumor cells. As a result, this approach appeared to be
successful. In the context of metastatic bone disease, the
principles are the same in any type of cancer, with an in-
creasingly targeted approach to and individualization of
therapy [13].
In conclusion, the outcome of the present case sug-
gests that AFTV in combination with concomitant ad-
ministration of palliative X-ray irradiation, adjuvant CEF,zoledronic acid, and aromatase inhibitors eradicates
skeletal metastasis of breast carcinoma with enhance-
ment of a specific anti-tumor immune reactivity. A lar-
ger scale clinical study is necessary to confirm the
efficacy of AFTV treatment in skeletal metastases of
breast carcinomas.
Consent
Written informed consent in English and Japanese was
obtained from the patient for publication of this case re-
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